eye-care-public-health-congress-2018-tracks

8 / 18

Page 24
Note:
Eye Care 2018 & Public Health Congress 2018 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 2
S e p t e m b e r 0 3 - 0 4 , 2 0 1 8 | L i s b o n , P o r t u g a l
alliedacademies Joint Event on
PUBLIC HEALTH, EPIDEMIOLOGY AND NUTRITION
OCULAR PHARMACOLOGY AND EYE CARE
&
World Congress on
19th International Conference on
Umur Kayabasi, Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C4-011
INHIBITION OF MTOR PATHWAY TO
PREVENT PHOTORECEPTOR CELL DAMAGE
Umur Kayabasi
Uskudar University, Turkey
Introductıon: mTOR is a cytoplasmic kinase that regulates cell growth and
metabolism in response to mitogens (such as IGF-I and vascular endothelial
growth factor (VEGF)), nutrients (amino acids, glucose and fatty acids),
hormones including insulin and cytokines. This pathway is essential for
development and growth of the young organism. But later in life, when growth
has been completed, mTOR drives cellular and organismal aging by acquiring
pro-inflammatory and signal resistant characteristics. mTOR pathway also
takes part in retinal degenerative diseases.
Methods: 10 patients with mid stage retinitis pigmentosa (RP) were treated
by intravitreal rapamycin and oral metformin plus resveratrol for six months.
10 other RP patients were given placebo. The average age of the patients was
28. After one year, change in visual acuity and visual fields (VF) was recorded.
Results: Difference in change in visual acuity did not reach a significant
statistical result between the two groups whilst the visual fields were either
protected or slightly improved in the treatment group. The difference in mean
deviation before and after one year follow up between the two groups was
statistically significant. (P:0.001) VF deteriorated in the placebo group, but
was preserved in the Treatment group.
Conclusion: Inhibition ofmTORmaintains cellular proteostasis and attenuates
oxidative stress by reducing misfolded protein synthesis and augmenting
autophagy to remove misfolded proteins caused by gene mutations. The
combination of rapamycin, metformin and resveratrol may help to stabilize
VF loss in hereditary retinal diseases.
Umur Kayabasi is a graduate of Istanbul Medical Fac-
ulty. After working as an Assistant in Ophthalmology,
he completed his clinical fellowship program of Neu-
ro-Ophthalmology and Eectrophysiology at Michigan
State University in 1995. After working as a Consul-
tant Neuro- Ophthalmologist in Istanbul, he worked at
Wills Eye Hospital for three months as an observer. He
has been working at World Eye Hospital since 2000.
He has chapters in different neuro- ophthalmology
books, arranged international symposiums, attended
TV programs to advertise the neuro-ophthalmology
subspecialty. He has also given lectures at local and
international meetings, plus published papers in neuro
ophthalmology.
BIOGRAPHY